Molecular monitoring for patients with chronic myeloid leukaemia (CML) has become an
important practice in the era of imatinib therapy. For successful widespread introduction into …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

The management of hematologic malignancies, including chronic myeloid leukemia (CML),
chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL), has led the way …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …

The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid
leukaemia (CML) serves as a model for molecularly targeted therapy of cancer,,,, but at least …

We have previously reported on the efficacy and tolerability of hyper-CVAD regimen
(cyclophosphamide, vincristine, Adriamycin, and dexamethasone) and imatinib followed by …

Imatinib mesylate, an inhibitor of the Bcr-Abl tyrosine kinase, has modest activity in
refractory/relapsed Philadelphia chromosome (Ph)-positive acute lymphocytic leukemia …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …

Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia
(CML). However, most patients treated with 400 mg imatinib daily have variable levels of …

BACKGROUND Little is known regarding long‐term prognosis among patients with
Philadelphia chromosome (Ph)‐positive chronic myelogenous leukemia (CML) who achieve …